Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 28

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 28
---
. KAKEN PHARMACEUTICAL CO., LTD. (Kaken Parent) Kaken Parent develops, produces, and sells pharmaceuticals and agrochemicals. Kaken Parent’s products are mainly for orthopedics and dermatology. Kaken Parent also manufactures feed additives. KAKEN INVESTMENTS INC. (Kaken) Kaken was formed by Kaken Parent on December 13, 2024, for the purpose of engaging in the transactions contemplated by the Divestiture Agreement. Kaken has not engaged in any business activities other than as incidental to its formation and in connection with the transactions contemplated by the Divestiture Agreement. Reasons for the Divestiture(see page 60) In the course of reaching its determination and recommendation to approve the Divestiture Agreement and the transactions contemplated by the Divestiture Agreement, Aadi’s board of directors considered a number of potentially supportive factors in its deliberations, including:

| • |     | information concerning Aadi’s current and future business, financial performance and condition, assets and 
 liabilities, operations, risks, management and competitive position;                                       |

- 18 -

| • |     | current financial market conditions and historical market prices, volatility and trading information with respect 
 to the common stock of Aadi;                                                                                      |

| • |     | Aadi’s consideration of possible strategic alternatives, including entering into a transaction with another 
 party or liquidating the assets of Aadi;                                                                    |

| • |     | the cessation of the PRECISION1 trial in light of the analysis by the Independent Data Monitoring Committee that       
 demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval; |

| • |     | the consideration to be received by Aadi in the Divestiture; |

| • |     | the terms of the Divestiture Agreement, including the conditions to closing the Divestiture set forth therein and                                                                                                                               
 the terms governing Aadi’s ability to solicit and evaluate competing acquisition proposals or other proposals for competing strategic transactions (including the ability of Aadi’s board of directors to withdraw its recommendation that Aadi 
 stockholders vote in favor of the Divestiture if Aadi’s board of directors receives a superior proposal, subject to certain additional provisions and exceptions);                                                                              |

| • |     | the extensive process undertaken by Aadi’s board of directors and Leerink Partners to identify and evaluate                                                                                                                                             
 strategic alternatives available to Aadi, during which Leerink Partners contacted a total of 31 potentially interested parties